New drug TAK-625 shows promise for rare liver disease in kids
NCT ID NCT05543174
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 study tested TAK-625 (maralixibat) in 7 Japanese children with Alagille syndrome, a rare genetic liver disorder. The goal was to see if the drug reduces bile acid levels and itching, and to find the best dose. Participants took the drug daily for up to 34 months, with regular clinic visits to monitor safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-625 (maralixibat chloride)
- What this could lead to
- If it works, this could lead to a treatment that reduces bile acid buildup and itching in children with Alagille syndrome, improving their daily life.
- What could go wrong
- This is a very small, completed study with only 7 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
-
Kindai University Nara Hospital
Ikoma, Nara, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Miyagi Children's Hospital
Sendai, Miyagi, Japan
-
Osaka University Hospital
Suita, Osaka, Japan
-
Saitama Prefectural Children's Medical Center
Saitama, Japan
-
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
-
Yokohamashi Tobu Hospital
Yokohama, Kanagawa, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.